ProCE Banner Activity

Updated Results From a Phase Ib/IIa Trial of Rovadicitinib for Glucocorticoid-Refractory or Dependent Chronic Graft-vs-Host Disease

Conference Coverage
Slideset

Updated results from the phase Ib/IIa trial of rovadicitinib suggest that this small molecule JAK/ROCK inhibitor elicits a high clinical response rate, has a manageable safety profile, and reduces corticosteroid dosing among patients with steroid-refractory or steroid-dependent chronic graft-vs-host disease.

Released: December 16, 2024

Expiration: December 15, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation